Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancer stem cells (CSCs) have increased resistance to cancer chemotherapy. They can be enriched as drug-surviving CSCs (D-CSCs) by growth with chemotherapeutic drugs, and/or by sorting of cells expressing CSC markers such as aldehyde dehydrogenase-1 (ALDH). CSCs form colonies in agar, mammospheres in low-adherence cultures, and tumors following xenotransplantation in Scid mice. We hypothesized that tranilast, a non-toxic orally active drug with anti-cancer activities, would inhibit breast CSCs. METHODOLOGY/FINDINGS: We examined breast cancer cell lines or D-CSCs generated by growth of these cells with mitoxantrone. Tranilast inhibited colony formation, mammosphere formation and stem cell marker expression. Mitoxantrone-selected cells were enriched for CSCs expressing stem cell markers ALDH, c-kit, Oct-4, and ABCG2, and efficient at forming mammospheres. Tranilast markedly inhibited mammosphere formation by D-CSCs and dissociated formed mammospheres, at pharmacologically relevant concentrations. It was effective against D-CSCs of both HER-2+ and triple-negative cell lines. Tranilast was also effective in vivo, since it prevented lung metastasis in mice injected i.v. with triple-negative (MDA-MB-231) mitoxantrone-selected cells. The molecular targets of tranilast in cancer have been unknown, but here we demonstrate it is an aryl hydrocarbon receptor (AHR) agonist and this plays a key role. AHR is a transcription factor activated by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polycyclic aromatic hydrocarbons and other ligands. Tranilast induced translocation of the AHR to the nucleus and stimulated CYP1A1 expression (a marker of AHR activation). It inhibited binding of the AHR to CDK4, which has been linked to cell-cycle arrest. D-CSCs expressed higher levels of the AHR than other cells. Knockdown of the AHR with siRNA, or blockade with an AHR antagonist, entirely abrogated the anti-proliferative and anti-mammosphere activity of tranilast. Thus, the anti-cancer effects of tranilast are AHR dependent. CONCLUSION/SIGNIFICANCE: We show that tranilast is an AHR agonist with inhibitory effects on breast CSCs. It is effective against CSCs of triple-negative breast cancer cells selected for anti-cancer drug resistance. These results suggest it might find applications in the treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895 · cited 4×
“6A) as compared to 3methylcholanthrene (3-MC), which is a classic high affinity AHR agonist [27].”
BackgroundInfluentialKao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006146 · Cited by 788 · cited 1×
“[53] show that breast cancer cell lines can be subdivided into similar subtypes as clinical tumors.”
BackgroundFurness, S. G. B., & Whelan, F. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.09.004 · Cited by 63 · cited 21×
“It appears that TCDD can either enhance or suppress the incidence of cancer depending on the target cell and other factors [47].”
BackgroundInfluential
Cited by
The Aryl Hydrocarbon Receptor in Barrier Organ Physiology, Immunology, and Toxicology
Esser, C., & Rannug, A. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009001 · Cited by 501
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
Salinomycin as a Drug for Targeting Human Cancer Stem Cells
Naujokat, C., & Steinhart, R. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/950658 · Cited by 351
Tranilast: A review of its therapeutic applications
Darakhshan, S., & Pour, A. B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2014.10.009 · Cited by 322
Prud’homme, G. J., & Glinka, Y. (2012) · Oncotarget · doi:10.18632/oncotarget.626 · Cited by 275
Self-citationRole of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
Safe, S., Lee, S.-O., & Jin, U.-H. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft128 · Cited by 264
Al-Dhfyan, A., Alhoshani, A., & Korashy, H. M. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0570-y · Cited by 191
“At the constitutive level, five breast cancer cell lines that exhibit different hormonal heterogenicity, particularly SKBR-3 (HER2+), MCF-7 and T47D (ER+), and HS587T and MD-MB 231 (TNBC), were utilized to explore the differential constitutive expression of AhRregulated genes, CYP1A1 and CYP1B1 in the mammospheres (CS…”
ResultInfluentialRole of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target
Kolluri, S. K., Jin, U.-H., & Safe, S. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1981-2 · Cited by 173
“There is also evidence that the AhR can be targeted in cancer stem cells; for example, the AhR-active pharmaceutical tranilast significantly inhibits breast cancer stem cell growth and metastasis in vivo using MDAMB-231 drug-surviving cancer stem cells (Prud’homme et al. 2010).”
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
“Paradoxically, AHR hyperactivation with exogenous ligands may also lead to reduced breast cancer cell invasion (Hall et al., 2010; Prud ’ homme et al., 2010; Zhao et al., 2012; Safe et al., 2013; Jin et al., 2014), suggesting that endogenous and exogenous ligands may induce different signaling…”
BackgroundChemical approaches to targeting drug resistance in cancer stem cells
Sotiropoulou, P. A., Christodoulou, M. S., Silvani, A., Herold-Mende, C., & Passarella, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.002 · Cited by 100
Metadata
- Authors
- Prud'homme, G. J., Glinka, Y., Toulina, A., Ace, O., Subramaniam, V., & Jothy, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-11-03
- Volume
- 5
- Issue
- 11
- Pages
- e13831
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2134123270
- Cited by
- 141
- References
- 3
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.